Prophylactic use of clopidogrel in paediatric cardiac patients

Area of Science:

• Pediatric Cardiology
• Pharmacology
• Hematology

Background:

• Infants with congenital heart defects frequently experience thromboembolic complications despite aspirin therapy.
• Limited pharmacologic data exists for clopidogrel use in infants, with dosing uncertainties and known non-responder individuals.

Purpose of the Study:

• To evaluate the safety and efficacy of a 0.2 mg/kg/d dose of clopidogrel in infants with congenital heart defects when used in conjunction with aspirin.
• To assess the impact of clopidogrel on platelet function inhibition in this pediatric population.

Main Methods:

• A prospective monocentric study involving 14 infants (median age 5 months) with congenital heart defects.
• Patients received clopidogrel (0.18-0.24 mg/kg/d) plus aspirin (2-4 mg/kg/d).
• Platelet function was assessed using ADP stimulation tests (4 and 10 µmol/l) after 7 days of clopidogrel treatment.

Main Results:

• 93% of patients achieved effective platelet function inhibition (median aggregation 38% at 4 µmol/l ADP), with optimal response defined as 30-50% aggregation.
• All participants were identified as responders to the clopidogrel and aspirin regimen.
• No thromboembolic events or severe bleeding complications were observed during a median follow-up of 11 months.

Conclusions:

• A clopidogrel dose of 0.2 mg/kg/d, combined with aspirin, is safe and effective for inhibiting platelet function in infants with congenital heart defects.
• Monitoring platelet function is crucial for optimizing clopidogrel dosing and ensuring therapeutic efficacy in long-term treatment.
• This regimen offers a promising strategy for managing thromboembolic risk in this vulnerable pediatric population.